EGFR_Inhibitors_in_Advanced_NSCLC.pptVIP

EGFR Inhibitors in Advanced NSCLC Hematology Grand Rounds Tom Fong, M.D. January 4, 2008 Lung Cancer - Background Leading cause of cancer-related mortality 2007 statistics: 210k new cases 160k deaths ~87%: non-small cell lung cancer (NSCLC)* Median survival ~10 mos. (advanced stage) Lung Cancer - Epidemiology EGFR Background Epidermal growth factor receptor (EGFR): HER/ErbB family of transmembrane receptors Dimerizes on ligand binding Intracellular tyrosine kinase (TK) domain Activation leads to downstream effector pathways, cellular proliferation, etc. NSCLC: Activating mutations in TK do